Ebola is back in the news, and the current outbreak is worth taking seriously enough to understand properly — not because it’s about to land on our doorstep, but because it’s a genuinely unusual event with some uncomfortable gaps in it. Here’s the current picture, in plain terms.
What’s happening
This is the seventeenth recorded Ebola outbreak in the Democratic Republic of Congo since the disease was first identified in 1976, and it started only around five months after the previous one ended. It began in Ituri Province in the country’s east, was officially declared on 15 May 2026, and has since spread into North Kivu and South Kivu provinces.
As of the most recent figures, the DRC has passed 1,150 confirmed cases and over 300 confirmed deaths, with several hundred more currently hospitalised in isolation. Uganda has recorded around 20 confirmed cases, concentrated in the capital, Kampala, after cases arrived via travel from DRC rather than through local spread. By late June, this outbreak had already become the third-largest Ebola outbreak on record.
The World Health Organization declared it a Public Health Emergency of International Concern on 17 May — the organisation’s highest alert level, reserved for events judged to pose a serious cross-border risk requiring coordinated international action.
Why this one is different
The strain responsible is Bundibugyo virus, not the more familiar Zaire strain that caused the 2014 West Africa outbreak most people remember. That distinction matters more than it might sound.
The two licensed Ebola vaccines, along with the monoclonal antibody treatments developed since 2014, were built and approved specifically against the Zaire strain. WHO has already advised against using the existing vaccine in this outbreak, judging the evidence for cross-protection against Bundibugyo insufficient. In effect, the main tools that helped bring previous outbreaks under control aren’t confirmed to work here.
That leaves the response relying on the fundamentals: rapid case detection, contact tracing, isolation, infection control in treatment centres, and safe burial practices. Several candidate vaccines and treatments — including from Moderna, Oxford, and IAVI — have had funding fast-tracked and are heading into trials, but none are approved or in wide use yet.
Historically, Bundibugyo outbreaks have had somewhat lower fatality rates than Zaire Ebola, though still substantial — previous outbreaks of this strain have carried fatality rates in the region of 25–50%.
Why containment is proving hard
WHO’s own assessment isn’t especially reassuring on pace. An emergency response lead for WHO Africa recently rated the scale-up of the response at around three or four out of ten, against where it needs to be to bring the outbreak under control — despite hundreds of treatment beds and several functioning laboratories now in place.
The area worst affected sits in a region already dealing with insecurity and population displacement linked to ongoing conflict, which is compounding an already difficult job. Contact tracing follow-up rates have been running well below where they’d need to be for a fast-moving outbreak, and cross-border movement between DRC and Uganda is heavy, given how closely connected the communities either side of that border are.
Has it reached Europe?
Two cases have been confirmed in Europe so far, both directly linked to travel from the affected region rather than any local transmission: an American doctor medically evacuated to Germany after treating patients in DRC, and a French doctor confirmed positive after returning from a humanitarian mission there. Both cases were managed under isolation on arrival.
The European Centre for Disease Prevention and Control continues to assess the likelihood of infection for people living in the EU/EEA as very low, on the basis that Ebola requires direct contact with an infected person’s bodily fluids to spread — it isn’t airborne, and casual contact doesn’t transmit it. The UK Health Security Agency has made the same assessment for the UK: risk to the general public here remains very low.
The international response
Funding and support have moved reasonably quickly at government level. The UK has committed around £21 million toward the DRC response, plus a further £5 million specifically for developing diagnostics and treatments for the Bundibugyo strain, and helped launch a new Multi-Hazard Research Network to feed expert analysis into decision-making. The G7 issued a joint statement in mid-June calling for coordinated international action, and a continental plan led by Africa CDC and WHO is aiming to raise $518 million to support the wider regional response through November.
What this means for you
None of this points to a household-level threat here at home right now — Ebola simply doesn’t spread the way something like flu or Covid does, and the current risk assessment for the UK reflects that. But it’s a useful reminder of a point worth keeping in mind generally: outbreaks like this are becoming more frequent rather than less, and international funding announcements are not the same thing as knowing what you’d personally do if disease control measures — screening, restrictions, changes to travel or supply chains — started affecting daily life here, even indirectly.
Worth keeping an eye on how this develops over the coming months, particularly whether it starts moving beyond the current affected provinces. We’ll keep this page updated as the situation changes. Get The Book – Preparing for Lockdown